Consano Bio Assembles Advisory Team to Advance Non-Opioid Sciatica Drug

Chronic sciatica patients currently face limited options beyond temporary symptom management, a gap Consano Bio aims to bridge with its investigational biologic, C-1101. The Burlington-based firm has recruited a high-profile Scientific Advisory Board to navigate the regulatory and clinical hurdles of developing this first-in-class, non-opioid therapy.

Today, 15:44· Money Talk· 1,681 reads

Consano Bio Assembles Advisory Team to Advance Non-Opioid Sciatica Drug

The company’s lead candidate, C-1101, functions as a platelet-derived multi-protein biologic designed to modulate inflammation and stimulate cellular repair at the site of nerve injury. Administered via epidural injection, the treatment seeks to address the underlying causes of lumbosacral radiculopathy, a condition for which no FDA-approved pharmaceutical therapies currently exist.

To guide this development, Consano Bio has tapped former U.S. Surgeon General Jerome Adams and interventional orthopedics pioneer Christopher Centeno as key external advisors. The broader Scientific Advisory Board includes experts such as Harvard Medical School’s Mihir Kamdar, regulatory veteran Susan Stewart, transfusion medicine specialist Ralph Vassallo, and biologics manufacturing expert Li Malmberg. According to CEO Andrew Hall, this multidisciplinary oversight is essential to transition the program from clinical investigation to a viable disease-modifying treatment.

Consano Bio Assembles Advisory Team to Advance Non-Opioid Sciatica Drug

Comments (0)